{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:58:49Z","timestamp":1770821929793,"version":"3.50.1"},"reference-count":51,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["214958"],"award-info":[{"award-number":["214958"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2024,6,18]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The efficacy of belimumab in SLE has been demonstrated in randomised clinical trials, and its real-world effectiveness has been shown in studies in several countries. While belimumab was approved for treating SLE in China in 2019, data on its benefit in clinical practice are limited. This study will evaluate belimumab\u2019s effectiveness in China, using practical clinical measures, such as Lupus Low Disease Activity State (LLDAS), to add to the body of real-world evidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>The Real-world Effectiveness of beLImumAB in patients with systemic Lupus Erythematosus in China (RELIABLE) is an ambidirectional, observational descriptive cohort study across approximately 15 centres in China. Adults with SLE newly initiating belimumab with \u22651 measure of all five LLDAS components (SLE Disease Activity Index-2000; no new lupus disease activity; Physician Global Assessment; prednisolone-equivalent dose; immunosuppressants\/biologics use) in the 3 months preceding belimumab initiation (index date) will be eligible and retrospectively and\/or prospectively enrolled, depending on data availability. The retrospective follow-up will be \u22646 months, and retrospective and prospective patients will have a maximum 24-month follow-up. The primary objectives will be to describe the proportion of patients achieving LLDAS at 12 and 24 months post-index. The key secondary objective will be to describe the proportion of patients achieving LLDAS and each component at 3, 6, 9 and 18 months post-index. All data will be analysed descriptively; a statistical estimand will be applied to account for intercurrent events expected in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This study will comply with all applicable laws regarding patient privacy; institutional review board approval will be obtained before the study commencement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study will evaluate belimumab\u2019s effectiveness in patients with SLE initiating belimumab in clinical practice in China. Using LLDAS will provide clinicians with valuable insights into the impact of belimumab on the treat-to-target strategy with a relevant measure that can be repeated across the clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2024-001144","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T20:00:21Z","timestamp":1720728021000},"page":"e001144","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01345253","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Liya","family":"Fan","sequence":"first","affiliation":[{"name":"GSK, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiliu","family":"Tang","sequence":"additional","affiliation":[{"name":"GSK, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[{"name":"GSK, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"He","sequence":"additional","affiliation":[{"name":"IQVIA, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7219-9141","authenticated-orcid":false,"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University First Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6241-483X","authenticated-orcid":false,"given":"Patricia","family":"Juliao","sequence":"additional","affiliation":[{"name":"GSK, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"2025091512073961000_11.2.e001144.1","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025091512073961000_11.2.e001144.2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO;2-6"},{"key":"2025091512073961000_11.2.e001144.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035"},{"key":"2025091512073961000_11.2.e001144.4","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/annrheumdis-2023-eular.1822","article-title":"Ab1644\u2005incidence, prevalence, and burden of systemic lupus erythematosus in urban China, 2013-2017: a nationwide population-based study","volume":"82","author":"Li","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025091512073961000_11.2.e001144.5","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313499086"},{"key":"2025091512073961000_11.2.e001144.6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2478\/rir-2020-0009","article-title":"Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"1","author":"Li","year":"2020","journal-title":"Rheumatol Immunol Res"},{"key":"2025091512073961000_11.2.e001144.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.11.034"},{"key":"2025091512073961000_11.2.e001144.8","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310366572"},{"key":"2025091512073961000_11.2.e001144.9","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000031","article-title":"Clinical, laboratory and health-related quality of life correlates of systemic lupus erythematosus responder index response: a post hoc analysis of the phase 3 Belimumab trials","volume":"1","author":"Furie","year":"2014","journal-title":"Lupus Sci Med"},{"key":"2025091512073961000_11.2.e001144.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.106"},{"key":"2025091512073961000_11.2.e001144.11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.46497\/ArchRheumatol.2020.7405","article-title":"Burden of systemic lupus erythematosus on work productivity and daily living activity: a cross-sectional study among Malaysian multi-ethnic cohort","volume":"35","author":"Abu Bakar","year":"2020","journal-title":"Arch Rheumatol"},{"key":"2025091512073961000_11.2.e001144.12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2478\/rir-2022-0006","article-title":"The challenges and future perspective for the management of systemic lupus erythematosus in China: a concise annual report of 2020","volume":"3","author":"Tian","year":"2022","journal-title":"Rheumatol Immunol Res"},{"key":"2025091512073961000_11.2.e001144.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205171"},{"key":"2025091512073961000_11.2.e001144.14","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30105-5"},{"key":"2025091512073961000_11.2.e001144.15","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012787","article-title":"Slicc damage index score in systemic lupus erythematosus patients and its associated factors","volume":"97","author":"Ghazali","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2025091512073961000_11.2.e001144.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu148"},{"key":"2025091512073961000_11.2.e001144.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2025091512073961000_11.2.e001144.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299"},{"key":"2025091512073961000_11.2.e001144.19","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653"},{"key":"2025091512073961000_11.2.e001144.20","unstructured":"GSK . China\u2019s National Medical Products Administration approves Benlysta (belimumab) for patients with active lupus nephritis. Available: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/china-s-national-medical-products-administration-approves-benlysta-belimumab-for-adult-patients-with-active-lupus-nephritis\/ [Accessed Apr 2023]."},{"key":"2025091512073961000_11.2.e001144.21","unstructured":"EVERSANA . China issues 2020 national reimbursement drug list [Press Release]. 2021. Available: https:\/\/www.eversana.com\/2021\/01\/04\/china-2020-national-reimbursement-drug-list\/ [Accessed 14 Jun 2023]."},{"key":"2025091512073961000_11.2.e001144.22","first-page":"78","article-title":"Chinese expert consensus on the use of biologics in systemic lupus erythematosus","volume":"28","author":"Yan","year":"2024","journal-title":"Chin J Rheumatol"},{"key":"2025091512073961000_11.2.e001144.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2025091512073961000_11.2.e001144.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2025091512073961000_11.2.e001144.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2025091512073961000_11.2.e001144.26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001669","article-title":"Phase 3, long-term, open-label extension period of safety and efficacy of Belimumab in patients with systemic lupus erythematosus in China, for up to 6 years","volume":"8","author":"Zhang","year":"2022","journal-title":"RMD Open"},{"key":"2025091512073961000_11.2.e001144.27","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/keab883","article-title":"Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index","volume":"61","author":"Carter","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025091512073961000_11.2.e001144.28","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2019.20022","article-title":"Clinical outcomes in patients with systemic lupus erythematosus treated with Belimumab in clinical practice settings: a retrospective analysis of results from the observe study in Switzerland","volume":"149","author":"von Kempis","year":"2019","journal-title":"Swiss Med Wkly"},{"key":"2025091512073961000_11.2.e001144.29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40744-016-0047-x","article-title":"First real-world insights into Belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the observe Germany study","volume":"3","author":"Schwarting","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2025091512073961000_11.2.e001144.30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00296-017-3682-9","article-title":"Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving Belimumab in clinical practice settings: results from the observe Canada study","volume":"37","author":"Touma","year":"2017","journal-title":"Rheumatol Int"},{"key":"2025091512073961000_11.2.e001144.31","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s J , Andreu JL , Calvo J , et al . Evaluation of use of Belimumab in clinical practice settings (observe study) in Spain: health resource utilization and labour absenteeism. Value Health 2014;17. doi:10.1016\/j.jval.2014.08.1703","DOI":"10.1016\/j.jval.2014.08.1703"},{"key":"2025091512073961000_11.2.e001144.32","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1177\/0961203320947814","article-title":"Evaluation of Belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: results from a 24-month observe study in Argentina","volume":"29","author":"Babini","year":"2020","journal-title":"Lupus"},{"key":"2025091512073961000_11.2.e001144.33","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000118","article-title":"Response to Belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the observe study in the USA","volume":"3","author":"Collins","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2025091512073961000_11.2.e001144.34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030962","article-title":"Effectiveness and safety of Belimumab in Chinese lupus patients: a multicenter, real-world observational study","volume":"11","author":"Sun","year":"2023","journal-title":"Biomedicines"},{"key":"2025091512073961000_11.2.e001144.35","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-eurolupus.4"},{"key":"2025091512073961000_11.2.e001144.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025091512073961000_11.2.e001144.37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa120"},{"key":"2025091512073961000_11.2.e001144.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214427"},{"key":"2025091512073961000_11.2.e001144.39","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091512073961000_11.2.e001144.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"2025091512073961000_11.2.e001144.41","doi-asserted-by":"publisher","DOI":"10.1002\/art.41253"},{"key":"2025091512073961000_11.2.e001144.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.02.014"},{"key":"2025091512073961000_11.2.e001144.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209519"},{"key":"2025091512073961000_11.2.e001144.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211613"},{"key":"2025091512073961000_11.2.e001144.45","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30037-2"},{"key":"2025091512073961000_11.2.e001144.46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew377"},{"key":"2025091512073961000_11.2.e001144.47","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10067-020-05315-w","article-title":"Lupus low disease activity (SLE) in patients treated with Belimumab: a single-center real-life experience (2016-2019)","volume":"40","author":"Scheinberg","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025091512073961000_11.2.e001144.48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074044","article-title":"Clinical response Trajectories and drug persistence in systemic lupus erythematosus patients on Belimumab treatment: a real-life, multicentre observational study","volume":"13","author":"Nikoloudaki","year":"2022","journal-title":"Front Immunol"},{"key":"2025091512073961000_11.2.e001144.49","doi-asserted-by":"publisher","DOI":"10.1002\/art.40571"},{"key":"2025091512073961000_11.2.e001144.50","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000357","article-title":"Real-world treatment patterns, Healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with Belimumab: a retrospective analysis of claims data in the USA","volume":"7","author":"Bell","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025091512073961000_11.2.e001144.51","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","article-title":"Real-world effectiveness of Belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the observe studies","volume":"7","author":"Collins","year":"2020","journal-title":"Rheumatol Ther"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T19:07:52Z","timestamp":1757963272000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,11]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/lupus-2024-001144"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001144","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}